Mercury II - Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin With Rosuvastatin in High Risk Subjects With Type IIa and IIb Hypercholesterolemia

An Open Label, Randomized, Multi-Center, Phase IIIB, Parallel Group Switching Study to Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin With Rosuvastatin in High Risk Subjects With Type IIa and IIb Hypercholesterolemia.

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00654407

Enrollment

4875

Registered

2008-04-08

Start date

2001-11-30

Completion date

2004-09-30

Last updated

2009-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercholesterolemia

Keywords

Cholesterol, hypercholesterolemia, Coronary Heart disease, low density lipoproteins, Rosuvastatin, Atorvastatin, simvastatin

Brief summary

The purpose of this study is to determine whether treatment with rosuvastatin following atorvastatin or simvastatin treatment will improve health outcomes for patients at high risk of Coronary heart disease compared to atorvastatin and simvastatin alone.

Interventions

DRUGRosuvastatin

DRUGAtorvastatin

DRUGSimvastatin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Discontinuation of all cholesterol lowing drugs, including dietary supplements. * Documented history of, or high risk of coronary heart disease or other established atherosclerotic disease.

Exclusion criteria

* The use of lipid lowering drugs or dietary supplements after Visit 1. * Active arterial disease eg Unstable angina, or recent arterial surgery * Uncontrolled hypertension, hypothyroidism, alcohol or drug abuse. * Abnormal laboratory parameters as defined in the protocol.

Design outcomes

Primary

Measure	Time frame
Low density Lipoprotein cholesterol level - reaching internationally recognised LDL cholesterol goal levels.	16 weeks

Secondary

Measure	Time frame
Percentage change in other cholesterol & triglyceride measures	16 weeks
Safety evaluation	8 & 16 weeks
To compare the efficacy of rosuvastatin with atorvastatin and simvastatin	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 5, 2026